Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

Jason Lettmann

AddedMar 31, 2024

UpdatedMay 31, 2026

Jason Lettmann

Jason Lettmann

Board Member, ALX Oncology Holdings

Crunchbase LinkedIn

Jason Lettmann's Career

ALX Oncology Holdings

ALX Oncology Holdings

South San Francisco, CA, US

Board Member· Board

Atsena Therapeutics

Atsena Therapeutics

Durham, NC, US

Board Member· Board

Cerevance

Cambridge, MA, US

Board Member· Board

Spine Wave

Shelton, CT, US

Board Member· Board

Second Genome

South San Francisco, CA, US

Board Member· Board

Relievant Medsystems

Relievant Medsystems

Edina, MN, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Jason Lettmann's Career

ALX Oncology Holdings

ALX Oncology Holdings

Public712020South San Francisco, CA, US

Board Member· Board

Leadership at ALX Oncology Holdings

Corey GoodmanBoard Member

Jaume PonsFounder

Jack NielsenBoard Member

Similar to ALX Oncology Holdings

OncolixHouston, TX, USCancer Treatmentest. 2007OncolixHouston, TX, US · est. 2007

Oncolix: A clinical-stage biotech firm innovating therapeutic proteins for cancer treatment.

Series A · $8.5M30

Allogene TherapeuticsSouth San Francisco, CA, USCancer Therapiesest. 2017Allogene TherapeuticsSouth San Francisco, CA, US · est. 2017

San Francisco-based Allogene Therapeutics pioneers AlloCAR T™ therapies for cancer, revolutionizing allogeneic cell therapy.

Public · $781.8M361

Immune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35

OncoSpherixAtlanta, GA, USCancer Treatmentsest. 2018OncoSpherixAtlanta, GA, US · est. 2018

OncoSpherix, Inc.: Advancing novel cancer treatments with proprietary therapeutics to enhance survival and quality of life.

Atsena Therapeutics

Atsena Therapeutics

Series B$87.6M552019Durham, NC, US

Board Member· Board

Leadership at Atsena Therapeutics

Sarah BhagatBoard Member

Jennifer WellmanBoard Member

Patrick RitschelCEO

Sanford BoyeCo-Founder

Jacqueline GrantBoard Member

Shannon BoyeCo-Founder

Similar to Atsena Therapeutics

Capsida BiotherapeuticsBuena Park, CA, USGene Therapyest. 2019Capsida BiotherapeuticsBuena Park, CA, US · est. 2019

Capsida: A US-based biotech firm specializing in monogenetic and sporadic CNS/non-CNS disorders.

Late Stage Private · $140M132

Apertura Gene TherapyNew York City, NY, USGene Therapyest. 2021Apertura Gene TherapyNew York City, NY, US · est. 2021

Apertura Gene Therapy: A biotech firm pioneering gene therapy for debilitating diseases.

Series A · $67M29

AgtcAlachua, FL, USGene Therapyest. 1999AgtcAlachua, FL, US · est. 1999

AGTC: A biotech firm conducting clinical trials for AAV-based gene therapies for rare diseases.

Public · $195.1M350

Lacerta TherapeuticsAlachua, FL, USGene Therapyest. 2017Lacerta TherapeuticsAlachua, FL, US · est. 2017

Lacerta Therapeutics: A clinical-stage gene therapy firm innovating treatments for CNS and lysosomal diseases.

Series C · $30M45

Cerevance

Series B$142.5M622016Cambridge, MA, US

Board Member· Board

Leadership at Cerevance

Mike PooleBoard Member

Mark CarltonCo-Founder

Craig ThompsonCEO

Matthias KleinzBoard Member

David C. LubnerBoard Member

Similar to Cerevance

NeurolinkSan Antonio, TX, USMedical Devicesest. 2008NeurolinkSan Antonio, TX, US · est. 2008

Neurolink Medical, Inc.: Pioneering CNS disorder treatments from San Jose, California.

Seed · $3.9M23

NeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30

Chase TherapeuticsWashington, D.C., DC, USPharmaceuticalsest. 2017Chase TherapeuticsWashington, D.C., DC, US · est. 2017

Chase Therapeutics: An early-stage pharmaceutical company innovating superior brain disease treatments.

Series B · $25.3M175

Spine Wave

Series A$145.5M1222001Shelton, CT, US

Board Member· Board

Leadership at Spine Wave

Harry T ReinBoard Member

Ryan DrantBoard Member

John PaffordCo-Founder

Mark LoguidiceBoard Member

Similar to Spine Wave

Spinal USAParsippany-Troy Hills, NJ, USMedical Devicesest. 2005Spinal USAParsippany-Troy Hills, NJ, US · est. 2005

Precision Spine: A US-based global provider of quality spinal products for healthcare professionals.

Angel · $258.4k75

SpineOvationsCarlsbad, CA, USMedical Devicesest. 2004SpineOvationsCarlsbad, CA, US · est. 2004

SpineOvations: Innovating spinal disorder diagnosis and treatment through advanced medical technology.

SpineologySt. Paul Park, MN, USMedical Devicesest. 1997SpineologySt. Paul Park, MN, US · est. 1997

Spineology, Inc.: A US-based producer and distributor of advanced medical instruments for spinal care.

Series A · $28.6M103

SpineFormCincinnati, OH, USMedical Devicesest. 2004SpineFormCincinnati, OH, US · est. 2004

SpineForm LLC: A US-based medical device company specializing in scoliosis treatment solutions.

Pre-Seed · $2.3M5

Second Genome

Acquired$62.5M02009South San Francisco, CA, US

Board Member· Board

Leadership at Second Genome

Brad MargusBoard Member

Jill CarrollBoard Member

Janet WarringtonCo-Founder

Todd DeSantisCo-Founder

Karim DabbaghBoard Member

Mike CarusiBoard Member

Relievant Medsystems

Relievant Medsystems

Public$273.6M592006Edina, MN, US

Board Member· Board

Leadership at Relievant Medsystems

Tyler BinneyCEO

Kevin HykesBoard Member

Justin KleinBoard Member

Samit PatelFounder

Brent AhrensBoard Member

Similar to Relievant Medsystems

Relevium MedicalGalway, County Galway, IEPain Treatmentsest. 2019Relevium MedicalGalway, County Galway, IE · est. 2019

Innovative biopharmaceutical company providing superior pain treatments.

RaymedicaMinneapolis, MN, USMedical Devicesest. 1990RaymedicaMinneapolis, MN, US · est. 1990

Raymedica, Inc. is a medical device manufacturer, innovating surgical solutions for low back pain treatment worldwide.

Series A · $10M30

Intact MedicalFramingham, MA, USMedical Devicesest. 2002Intact MedicalFramingham, MA, US · est. 2002

US-based Intact Medical Corp. develops minimally invasive systems.

Pre-Seed · $25.7M7

Channel MedsystemsSan Francisco, CA, USMedical Devicesest. 2009Channel MedsystemsSan Francisco, CA, US · est. 2009

San Francisco-based Channel Medsystems develops and delivers non-invasive medical technology products.

Series A · $62.9M35

Jason Lettmann's Similar Executives & Operators

Willix HalimCEO · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

Jay Geoffrey WacherBoard Member · Bukalapak

Lau Eng BoonBoard Member · Bukalapak

WILL WEI CHENGBoard Member · DiDi

Dhirubhai H. AmbaniBoard Member · Reliance Retail

Ken KutaragiBoard Member · Rakuten

Takashi MitachiBoard Member · Rakuten

People Similar to Jason Lettmann

Stephen BlochBoard Member · Liquidia

PJ AnandBoard Member · Anuncia

Lawrence BlattBoard Member · Aligos Therapeutics

Steven EvansBoard Member · Oncolyze

Neal KollerCEO · PluroGen Therapeutics